Latest filing published 18 Feb 2026 for Johnson & Johnson.
Kathryn E. Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson (64 filings) and a Director at Labcorp Holdings Inc. (5), has filed 69 times between February 12, 2019 and February 18, 2026. The 9 sales total EUR 13.5 million, with a median of EUR 1,067,563. The largest, EUR 5,396,636, is from June 10, 2022; next come November 9, 2022 (EUR 2,822,999) and June 12, 2023 (EUR 1,853,017). No purchase is in the record, which holds 34 option exercises and 26 grants.
The yearly volume is 12 filings in 2022 and 11 in 2025 and 2026, against 4 in 2021. Eleven filings fall in the last 12 months, with no sale. The median publication delay is 4 days.
At Johnson & Johnson, 5 of Wengel's trades are within 30 days of a trade by Robert J. Decker, and 1 each for Ashley McEvoy, Jennifer L. Taubert, Peter Fasolo and Thibaut Mongon, all in the same direction.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 69 declarations